Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Neuspera Raises $26 Million in B Round, Led by China's 6 Dimensions

publication date: Jan 24, 2018

Neuspera Medical, a California neuromodulation company, completed the initial closing of a $26 million Series B round, led by 6 Dimensions Capital. 6 Dimensions was formed in 2017 by the merger of two China-US healthcare investors, Frontline BioVentures and WuXi Healthcare Ventures. Neuspera engineers miniaturized neuromodulation devices using both licensed and proprietary power transfer technologies. Neuspera's implanted modules are as much as 100 times smaller than its competition, the company says. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital